Abstract
To determine whether the high-flow nasal cannula (HFNC) is a more cost-effective alternative when compared to conventional oxygen therapy (COT) for decreasing invasive ventilation rates in the treatment of acute hypoxemic respiratory failure (HRF) in patients with Covid- 19 from the perspective of private health.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
